Advanced Solid Tumor Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following advanced solid tumor clinical trials:

An Observational Study of the Human Adaptive Immune Response (SHAIR) to Cancer in Adults with Advanced Solid Malignancies

Treatment: N/A
PI: Sara Keck, MD
Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707) 521-3833 ext. 1313
Resources and Links: None
Sponsor: Atreca

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment: MRTX849, Docetaxel
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Exact Sciences Corporation

A Phase II, Multicenter, Open-label study to evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)

Treatment: Trastuzumab deruxtecan (T-DXd)
PI: Ian Anderson, MD
Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04482309
Sponsor: AstraZeneca

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Treatment: Bozitinib (APL-101)
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03175224
Sponsor: Apollomics Inc.

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors

Treatment: ABBV-927 with ABBV-368, budigalimab (ABBV-181), and/or chemotherapy
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT03893955
Sponsor: AbbVie Inc.

A Multi- Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal and Breast Cancer

Treatment: Fruquintinib
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03251378

SEERPRO: A Prospective Blood Sample Collection Study To Evaluate a Panel of Protein-based-Biomarkers

Treatment: Ibrutinib, Everolimus, Docetaxel, Paclitaxel, Cetuximab, Pembrolizumab
PI: Manasa Vulchi, MD
Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Treatment: ladiratuzumab vedotin
PI: Ian Anderson, MD
Coordinator: Teresa Lund // Teresa.Lund@stjoe.org // (707) 521-3803 ext. 1103
Resources and Links: clinicaltrials.gov NCT No: NCT04032704

A Study of Repotrectinib(TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)

Treatment: Oral Repotrectinib
PI: Ian Anderson, MD
Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03093116

A Phase 1/2 Study of Galinpepimut-S in Combination with Pembrolizumab (MK-3475) in Patients with Selected Advanced Cancers (SELLAS)

Treatment agent: Galinpepimut-S (WT1 immunotx) + pembro
PI: Jarrod Holmes, MD
Study Coordinator: Tracy Foster // Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links: clinicaltrials.gov NCT No: NCT03761914

Our Providers

Our Locations